Intraperitoneal injection of SCD-targeted antisense oligonucleotide (ASO) in mice inhibits SCD in the liver and adipose, resulting in increased insulin sensitivity, decreased hepatic fatty acid synthesis, and prevention of HFD-induced obesity and hepatic steatosis (55). Here, SCD is linked to fatty liver disease.